DNA-Sequenzierung 2023-2033: Technologien, Märkte und Prognosen: IDTechEx
Grail announces study results validating methylation sequencing approach for multicancer testing | LabPulse.com
Illumina Says Grail Deal Won't Hold Back New Cancer Tests - BNN Bloomberg
Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal | TechCrunch
Cancer researchers question antitrust arguments against Illumina-Grail deal | Reuters
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection – enlightenbio Blog
Will Illumina's Purchase of Grail Kill Cancer-Test Competition? | Barron's
Illumina And Grail Together: A Perfect Marriage (NASDAQ:ILMN) | Seeking Alpha
Illumina and Grail CEOs defend their deal to investors
Illumina loses its grip | Evaluate
GRAIL - Products, Competitors, Financials, Employees, Headquarters Locations
FTC urges judge to unwind $7.1 bln Illumina-Grail merger | Reuters
San Diego sequencing giant Illumina to reunite with Grail for $8B in bid to detect cancer earlier - The San Diego Union-Tribune
Illumina may buy back Grail - Drug Discovery and Development
Illumina eyeing future of Grail as EU shoots down merger | pharmaphorum
Can Grail find the trail to early cancer detection?
FTC orders Illumina to divest cancer test maker Grail on competition grounds - MarketWatch
When Bad Antitrust Costs Lives: The Illumina/GRAIL Tragedy - Truth on the Market Truth on the Market
More than 400 Grail patients incorrectly told they may have cancer | Ars Technica
FTC trial over Illumina's acquisition of Grail kicks off - The San Diego Union-Tribune
Antitrust regulators expand their global reach. - The New York Times
